TAVANTA
Dead / Abandoned — Abandoned — no statement of use filed (as of 23 Nov 2025)
What this means for you
This application is over — abandoned 23 Nov 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 90845441
- Mark type
- Stylized text
- Filed
- 23 Jul 2021
- Published for opposition
- 07 Mar 2023
- Abandoned
- 23 Nov 2025
- Attorney of record
- C. BRANDON BROWNING
Goods and services
- Class 005 — Pharmaceuticals: Housemark for a full line of prescription pharmaceuticals for the treatment of cancer, anal fissures, cystic fibrosis; pharmaceuticals for treatment of cancer, and cystic fibrosis; pharmaceuticals exhibiting efficient drug release for the treatment of cancer, cystic fibrosis, and anal fissures
Owner
- Tavanta Therapeutics, Inc., Radnor, PA, US
- Tavanta Therapeutics, Inc., Radnor, PA, US
Prosecution history
- 25 Nov 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 25 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 24 Nov 2025 — CORRECTED NOA E-MAILED
- 24 Nov 2025 — ABANDONMENT - NO USE STATEMENT FILED
- 24 Nov 2025 — SOU EXTENSION 4 GRANTED
- 02 May 2025 — SOU EXTENSION 4 FILED
- 24 Nov 2025 — DIVISIONAL PROCESSING COMPLETE
- 02 May 2025 — DIVISIONAL REQUEST RECEIVED
- 17 Nov 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 30 Sept 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 02 May 2025 — TEAS REQUEST TO DIVIDE RECEIVED
- 02 May 2025 — SOU TEAS EXTENSION RECEIVED
- 04 Nov 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 05 Nov 2024 — SOU EXTENSION 3 GRANTED
- 05 Nov 2024 — SOU EXTENSION 3 FILED